ARCH Venture Fund X, L.P. — SEC insider filings
SEC reporting owner CIK 1757011. 13 insider filings on record with FilingPulse; latest filed 2026-11-02.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2021-02-10 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 12 legs across 7 filings — 13,597,514 shares, $104,099,958 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 78.
- Largest priced transaction: purchase of 1,500,000 shares @ $17.00 ($25,500,000) in Neumora Therapeutics, Inc., filed 2023-09-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 10% owner | 3 | 4 legs · 7,030,300 sh · $43,599,990 | — | 6 |
| Neumora Therapeutics, Inc. (NMRA) | 10% owner | 3 | 2 legs · 3,415,700 sh · $30,499,977 | — | 12 |
| Aspen Neuroscience, Inc. (ASPE) | 10% owner | 2 | 3 legs · 1,333,333 sh · $19,999,995 | — | 18 |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 3 | 3 legs · 1,818,181 sh · $9,999,996 | — | 28 |
| Erasca, Inc. (ERAS) | 10% owner | 1 | — | — | 8 |
| Verve Therapeutics, Inc. (VERV) | 10% owner | 1 | — | — | 6 |
Insider filings — ARCH Venture Fund X, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT | Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 more | EDGAR |
| 2026-10-29 | 3 | Aspen Neuroscience, Inc. (ASPE) jointly with ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2025-10-29 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P. | Purchase (P): 1,915,700 @ $2.61 | EDGAR |
| 2025-08-01 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 3,030,300 @ $3.30 | EDGAR |
| 2024-02-20 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Purchase (P): 3,200,000 @ $6.25 | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund X Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
| 2023-12-12 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P. | Other (J): 703,061 · Other (J): 1,176,593 | EDGAR |
| 2023-09-20 | 4 | Neumora Therapeutics, Inc. (NMRA) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners VII, LLC, ARCH Venture Partners VII, L.P., ARCH Venture Fund VII, L.P., ARCH Venture Partners VIII, LLC, ARCH Venture Fund VIII Overage, L.P. | Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 more | EDGAR |
| 2022-10-26 | 4 | Prime Medicine, Inc. (PRME) jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X Overage, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 more | EDGAR |
| 2021-07-20 | 4 | Erasca, Inc. (ERAS) jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., NELSEN ROBERT, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN | Conversion (C): 5,527,777 · Conversion (C): 5,527,777 · Conversion (C): 2,100,000 (derivative) · Conversion (C): 2,100,000 (derivative) · Conversion (C): 3,400,000 (derivative) · Conversion (C): 1,133,333 (derivative) · +2 more | EDGAR |
| 2021-06-23 | 4 | Verve Therapeutics, Inc. (VERV) jointly with ARCH Venture Partners X, LLC, ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN | Conversion (C): 1,254,404 · Conversion (C): 1,254,405 · Conversion (C): 7,107,024 (derivative) · Conversion (C): 7,107,023 (derivative) · Conversion (C): 4,508,144 (derivative) · Conversion (C): 4,508,146 (derivative) | EDGAR |
| 2021-02-10 | 4 | Sana Biotechnology, Inc. (SANA) jointly with CRANDELL KEITH, BYBEE CLINTON, Burow Kristina, GILLIS STEVEN | Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 more | EDGAR |
| 2021-02-10 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Conversion (C): 10,156,250 · Conversion (C): 10,156,250 · Conversion (C): 11,718,750 · Conversion (C): 11,718,750 · Conversion (C): 3,687,500 (derivative) @ $0 · Conversion (C): 3,687,500 (derivative) @ $0 · +8 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1757011 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs